Karen Yiu
Overview
Explore the profile of Karen Yiu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
467
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lam A, Hao Z, Yiu K, Chan S, Chan F, Sung J, et al.
Int J Cancer
. 2025 Jan;
PMID: 39825684
Long-term use of low-dose aspirin has been demonstrated to reduce cancer risk, but the duration of necessary medication use remains uncertain. This study aimed to investigate the long-term chemoprotective effect...
2.
Mok C, Tang Y, Tan C, Chong K, Chen C, Sun Y, et al.
J Infect
. 2024 Dec;
90(1):106374.
PMID: 39657850
Background: The emergence of SARS-CoV-2 variants necessitates ongoing evaluation of vaccine performance. This study evaluates and compares the safety and immunogenicity of the Comirnaty and Spikevax monovalent XBB.1.5 COVID-19 vaccines...
3.
Tang Y, Tan C, Chong K, Chen C, Sun Y, Yiu K, et al.
Int J Infect Dis
. 2024 Oct;
149:107271.
PMID: 39426493
Objectives: As the SARS-CoV-2 virus evolves more rapidly than vaccines are updated, T cell immunity potentially confers protection against disease progression and death from new variants. In this study, we...
4.
Cheng S, Lau J, Tsang L, Leung K, Lee C, Hachim A, et al.
J Clin Virol
. 2023 Dec;
170:105621.
PMID: 38056114
Background: Natural SARS-CoV-2 infection may elicit antibodies to a range of viral proteins including non-structural protein ORF8. RNA, adenovirus vectored and sub-unit vaccines expressing SARS-CoV-2 spike would be only expected...
5.
Hui D, Yung L, Chan K, Ng S, Lui G, Ko F, et al.
Int J Infect Dis
. 2023 May;
133:60-66.
PMID: 37182546
Objectives: We compared the risk of environmental contamination among patients with COVID-19 who received high-flow nasal cannula (HFNC), noninvasive ventilation (NIV), and conventional oxygen therapy (COT) via nasal cannula for...
6.
Mok C, Chen C, Zhao S, Sun Y, Yiu K, Chan T, et al.
Lancet Microbe
. 2023 Apr;
4(6):e418-e430.
PMID: 37086735
Background: The primary aim of using vaccines in public health responses to SARS-CoV-2 variants of concern is to reduce incidence of severe disease, for which T-cell responses are essential. There...
7.
Tsoi K, Lam A, Tran J, Hao Z, Yiu K, Chia Y, et al.
J Clin Hypertens (Greenwich)
. 2023 Mar;
26(12):1327-1341.
PMID: 36946438
Hypertension remains the world's leading cause of premature death. Interventions such as exercise, diet modification, and pharmacological therapy remain the mainstay of hypertension treatment. Numerous systematic reviews and meta-analyses demonstrated...
8.
Cheng S, Mok C, Li J, Ng S, Lam B, Jeevan T, et al.
J Clin Virol
. 2022 Sep;
156:105273.
PMID: 36081282
Background: BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC) Omicron (B.1.1.529) are spreading globally. They demonstrate higher transmissibility and immune escape. Objectives: Determine BA.2.12.1, BA.4 and BA.5 virus plaque...
9.
Cheng S, Mok C, Chan K, Ng S, Lam B, Luk L, et al.
Euro Surveill
. 2022 May;
27(18).
PMID: 35514306
BackgroundOmicron subvariant BA.2 circulation is rapidly increasing globally.AimWe evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants.MethodsUsing 50% plaque reduction...
10.
Cheng S, Mok C, Leung Y, Ng S, Chan K, Ko F, et al.
Nat Med
. 2022 Jan;
28(3):486-489.
PMID: 35051989
The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in the serum of convalescent or vaccinated individuals...